FDA recall, , Moderate risk
New York Blood Center Apheresis Platelets, Leukocytes Reduced
Apheresis Platelets, Leukocytes Reduced had a platelet count higher than acceptable.
Recall ended Sep 24, 2026. Still check yours.
Summary by Recall Canary from the FDA notice
What happened
New York Blood Center Inc recalled Apheresis Platelets, Leukocytes Reduced because leukoreduced Apheresis Platelets products with a platelet count higher than was acceptable were distributed. The recall began May 19, 2025, and the FDA classified it on September 24, 2026, adding it to the Enforcement Report on the same date. The product was distributed in Minnesota.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Compare these details with yours, then check the recall notice to see which units are recalled.
Apheresis Platelets, Leukocytes Reduced
Recall details
- Company began the recall
- Sold in
- Company
- New York Blood Center Inc
- Hazard
- Quality testing problem
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99154
- Recall number
- B-0213-2026
All recalls from New York Blood Center Inc
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA · Recall ended
In FDA's weekly enforcement report
Listed on Recall Canary
